Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2001-10-1
pubmed:abstractText
We recently demonstrated the feasibility of combining enhanced tumor-to-tissue contrast and PET imaging for immunoscintigraphic tumor localization in pancreas and colon carcinoma bearing nude mice. Contrast enhancement was obtained with a multistep targeting technique that consists of the sequential administration of an antitumor/antihapten bispecific antibody (BS-MAb), a blocker to saturate the antihapten binding sites of the BS-MAb that remains in circulation, and a low molecular weight Ga chelate, labeled with the positron emitter 68Ga, which serves as the hapten. To evaluate the efficacy of this pretargeting technique for breast cancer localization, we synthesized a BS-MAb from the F(ab')(2) fragments of the anti-MUC1 MAb 12H12 which reacts with the vast majority of human breast carcinomas, and the F(ab') fragment of an anti-Ga chelate MAb using a bifunctional chemical linker. The BS-MAb was tested for its affinity and its biokinetics in nude mice bearing a human mammary carcinoma. Equilibrium binding of the BS-MAb for mammary carcinoma cells was low (1.2 x 10(7) M(-1)) while the binding capacity of cells was high (8.4 x 10(6) BS-MAbs per cell). Tumor uptake of the 67Ga labeled chelate in pretargeted animals was to 5.8 +/- 0.8% iD/g resulting in a tumor-to-blood ratio of 2.6 at 1h postinjection. This compares with a ratio of 0.65 and 0.85 obtained with 125I-labeled native 12H12 at 24h and 48h postinjection. No difference in the tumor uptake of both the 68Ga and 67Ga labeled chelate was observed. PET imaging of mice, started 1h postinjection of the 68Ga chelate, clearly visualized all tumors.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0969-8051
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
821-8
pubmed:dateRevised
2009-11-3
pubmed:meshHeading
pubmed-meshheading:11578904-Animals, pubmed-meshheading:11578904-Antibodies, Monoclonal, pubmed-meshheading:11578904-Chelating Agents, pubmed-meshheading:11578904-Female, pubmed-meshheading:11578904-Gallium, pubmed-meshheading:11578904-Indicators and Reagents, pubmed-meshheading:11578904-Indium Radioisotopes, pubmed-meshheading:11578904-Iodine Radioisotopes, pubmed-meshheading:11578904-Isotope Labeling, pubmed-meshheading:11578904-Mammary Neoplasms, Experimental, pubmed-meshheading:11578904-Mice, pubmed-meshheading:11578904-Mice, Nude, pubmed-meshheading:11578904-Mucin-1, pubmed-meshheading:11578904-Mucins, pubmed-meshheading:11578904-Neoplasm Transplantation, pubmed-meshheading:11578904-Radiopharmaceuticals, pubmed-meshheading:11578904-Technetium, pubmed-meshheading:11578904-Tissue Distribution, pubmed-meshheading:11578904-Tomography, Emission-Computed
pubmed:year
2001
pubmed:articleTitle
Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET.
pubmed:affiliation
Department of Diagnostic and Therapeutic Radiology German Cancer Research Center, Heidelberg, Germany.
pubmed:publicationType
Journal Article